Abstracts Archive - Page 2388 of 2425 - ACR Meeting Abstracts

Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
William Bensen¹, Denis Choquette², Isabelle Fortin³, Alice V. Klinkhoff⁴, Susan M. Otawa⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…
Abstract Number: 496 • 2012 ACR/ARHP Annual Meeting
Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data 3 Outcomes: The Canadian Experience
Andrew Chow¹, Majed M. Khraishi², Jude F. Rodrigues³, Susan M. Otawa⁴ and Hayssam Khalil⁵, ¹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³Rheumatology, Windsor, ON, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The routine assessment of patient index data 3 (RAPID3) was recently designed as a pooled index of 3 patient-reported outcomes (PROs): physical function, pain…
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: 498 • 2012 ACR/ARHP Annual Meeting
LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
Alberto Cauli¹, Grazia Dessole¹, Giovanni Porru¹, Matteo Piga¹, Alessandra Vacca², Valentina Ibba¹, Pietro Garau¹ and Alessandro Mathieu¹, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology Unit - Medical Sciences, University of Cagliari, Cagliari, Italy
Background/Purpose: We previously reported increased expression of cell membrane RANKL in PBMC of patients with active rheumathoid arthritis (RA) which was down-regulated by anti TNF-α…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 500 • 2012 ACR/ARHP Annual Meeting
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Yoshihiro Hishitani¹, Yoshihito Shima¹, Toru Hirano¹, Keisuke Hagihara², Kosuke Ebina³, Yasuo Kunugiza⁴, Kenrin Shi³, Masashi Narazaki¹, Atsushi Ogata¹, Tetsuya Tomita⁵, Toshio Tanaka¹ and Atsushi Kumanogoh¹, ¹Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁴Orthopedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Dept of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibitors (TNF-Is) show inadequate response to TNF-Is. But it has not been clarified what is…
Abstract Number: 501 • 2012 ACR/ARHP Annual Meeting
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Elisabeth Lie, Siri Lillegraven, Karen M. Fagerli, Till Uhlig and Tore K. Kvien, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Randomized clinical trials in RA have until recently focused on patients (pts) with high disease activity, but the majority of pts in the clinic…
Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Elena Becerra¹, Geraldine Cambridge² and Maria J. Leandro², ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Abstract Number: 503 • 2012 ACR/ARHP Annual Meeting
Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
Xavier Mariette¹, RF. van Vollenhoven², Vivian P. Bykerk³, Marc de Longueville⁴, Catherine Arendt⁴, Kristel Luijtens⁵ and John J. Cush⁶, ¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ²Clinical Trials Unit Department of rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁵UCB Pharma, Brussels, Belgium, ⁶Baylor Research Institute, Dallas, TX
Background/Purpose: The safety of certolizumab pegol (CZP) in rheumatoid arthritis (RA) has been reported in previous pooled analyses of clinical trials. An update of long-term…
Abstract Number: 504 • 2012 ACR/ARHP Annual Meeting
Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 Receptor Act by Competitive Inhibition of Acetylcholine-Mediated Receptor Signalling in Sjögren’s Syndrome
Michael W. Jackson¹, Isabell Bastian² and Thomas P. Gordon³, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, Allergy and Arthritis, Flinders University and Flinders Medical Centre, Adelaide, Australia, ³Immunology Allergy & Arthritis, Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Primary Sjögren’s syndrome (SS) is a systemic autoimmune disorder characterized by exocrine failure and widespread autonomic dysfunction. Functional autoantibodies (Abs) directed against the muscarinic…
Abstract Number: 505 • 2012 ACR/ARHP Annual Meeting
Characterization of an in Vitro Model of Human Salivary Gland for Studying Sjögren Syndrome (SS)
M. Jesus Dominguez-Luis¹, M.Teresa Arce-Franco¹, Estefania Armas-Gonzalez¹, Ada Herrera-Garcia¹, Teresa Giraldez², Pablo Miranda², Diego Alvarez de la Rosa³, Jose Garcia-Verdugo⁴, Carlos Martinez-Jimeno⁵ and Federico Diaz-Gonzalez¹, ¹Rheumatology Service. Hospital Universitario de Canarias., La Laguna, Spain, ²Unidad de Investigación of Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain, ³Department of Physiology. Universidad de La Laguna,, La Laguna, Spain, ⁴Cellular Morphology Laboratory, Centro de Investigación Príncipe Felipe., Valencia, Spain, ⁵Maxilofacial Department, Hospital Universitario de Canarias,, La Laguna, Spain
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune exocrinopathy of unknown etiology that is characterized by decreased salivary secretion (xerostomy) and lacrimal (xerophthalmy). Histopathological lesions…
Abstract Number: 506 • 2012 ACR/ARHP Annual Meeting
Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren’s Syndrome
Alessia Gallo¹, Mayank Tandon¹, Shyh-Ing Jang², Hwei Ling Ong², Indu Ambudkar², Gabor G. Illei³ and Ilias Alevizos⁴, ¹Sjogren's Clinic, NIDCR, Bethesda, MD, ²Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose: Loss of secretory function of salivary glands is one of the most important functional effects of Sjögren’s syndrome (SS), a chronic systemic autoimmune disease.…
Abstract Number: 507 • 2012 ACR/ARHP Annual Meeting
Expression of Micrornas (miRNAs) Predicted to Target Ro/SSA and La/SSB Autoantigens in Sjögren’s Syndrome (SS)
Vasiliki C. Gourzi¹, Efstathia K. Kapsogeorgou¹, Nikolaos C. Kyriakidis¹, Menelaos N. Manoussakis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: microRNAs (miRNAs) are key post-transcriptional regulators of gene expression and might be implicated in the over-expression of Ro/SSA and La/SSB autoantigens in the salivary…
Abstract Number: 508 • 2012 ACR/ARHP Annual Meeting
TLR3-Signaling Induces the Expression of Ro/SSA and La/SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs)
Nikolaos C. Kyriakidis¹, Efstathia K. Kapsogeorgou¹, Vasiliki C. Gourzi¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Previous studies have shown that the mRNA expression levels of the Ro52/TRIM21, Ro60/TROVE2 and La/SSB intracellular autoantigens are elevated within the immunopathologic lesions of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].